Singapore’s TauRx Faces U.S. Delays With Alzheimer’s Drug Plans
This article was originally published in PharmAsia News
Executive Summary
Recent reports that Alzheimer's drug Rember (methylthionium) of Singapore's TauRx would head into Phase III trials soon for U.S. approval in the wake of favorable Phase II trials may have been premature. It turns out the company has not filed an IND application in the United States and has not completed any large-species toxicology studies. TauRx Chairman Claude Wischik said he hoped both the studies could be done in parallel with an IND review. He added that the U.S. trials would be conducted with a different formulation than the one that just cleared Phase II trials in the United Kingdom and Singapore. (Click here for more